Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
Related Questions
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
In what scenarios outside of cryptococcal meningitis do you use flucytosine as adjunctive antifungal therapy?
Do you recommend immunomodulating treatments such as steroids or IVIG for West Nile Virus neuroinvasive disease?
How do you approach the use of Paxlovid in patients with COVID-19 and CKD Stage 4?
How do you manage gram-negative bacteremia in a patient with an aortic bypass graft, for whom there is low clinical suspicion for active graft infection?
How do you balance diagnostic stewardship and high value cost-conscious care when working up a patient with newly diagnosed HIV/AIDS admitted to the ICU with shortness of breath who most likely has PJP pneumonia or cryptococcal infection but is at risk of multiple other pathogens?
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
When would you consider long-term suppressive antibiotic therapy in patients with chronic or recurrent bacterial prostatitis who continue to experience symptoms despite multiple courses of antibiotics?
How do you decide on supportive care vs empiric antibiotics in a patient with suspected aspiration pneumonitis (i.e., witnessed macroaspiration event within the past 24 hours) but with features that could suggest pneumonia (e.g., acute respiratory distress, fever, leukocytosis, pulmonary infiltrates, etc.)?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
